Private Growth

We seek to invest in highly innovative technology and life sciences businesses

The Sands Capital Advantage

Access

In growth equity, deal awareness is not a differentiator. The fastest-growing companies are relatively easy to identify. However, deal access is a differentiator. The most promising growth equity companies have highly competitive financing rounds where entrepreneurs choose partners.

We believe Sands Capital gains access to deals because we are recognized as an ideal partner for long-term growth.

Selectivity

Selectivity requires deep knowledge across the public and private markets, a repeatable process, valuation discipline, and conviction. We believe our six criteria framework instills the discipline to only invest in exceptional growth businesses at fair valuations.

We believe our processes and experience give us the conviction to work with the businesses that drive long-term returns.

Value-add

Even the best businesses can benefit from strategic partners with business-model insight and deep domain knowledge. We seek to add value beyond financial support in the form of strategic and operational guidance, pre-IPO advice, and introductions focused on maximizing long-term opportunities.

 We believe our focus and depth of resources enable us to positively impact long-term outcomes for both businesses and our investors.

Global Innovation

Our global innovation strategy is at the nexus of our public and private strategies and seeks to invest in the best private technology business with the potential to become leading public companies.

Life Sciences Pulse

Our life sciences strategy seeks to invest in promising life sciences companies that we believe are at the heart of a technological and scientific revolution in healthcare.

News & Events

Announcements
Sands Capital Names Ian Ratcliffe to Executive Management Team
Ian has been instrumental in the development of the venture and private life sciences investing programs. His selection to the leadership team comes as Sands Capital continues to build its private market capabilities.
In The News
China’s Changing Priorities May Offer Opportunities in Select Businesses
Investors may look selectively to businesses supported by China’s emphasis on health and wellness, domestic brands, and higher-value manufacturing.
Announcements
Sands Capital Closes $560 Million Life Sciences Fund
This is Sands Capital’s second life sciences-dedicated fund, and the team will continue investing with an emphasis on private therapeutics, diagnostics, and life sciences tools businesses.
Events
Identity Intelligence is Critical to Cybersecurity in Ever-More Digital World
The pervasiveness of online activities demands new approaches to verifying identities.
Events
Life Science Innovation Central to Next Decade of Investment Opportunities
At the Pensions & Investment’s Private Market Virtual Series, Frank Sands discusses how innovations in life sciences could drive wealth creation opportunities over the next decade.